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Abstract
Background: the aim was to verify the association between
Major Depressive Disorders (MDD) and the risk of premature
death in people with oncological diseases, and to collect evidence
about the causality of a possible association from a longitudinal
perspective.
Design and Method: it is a cohort study lasting 9 months,
involving people with solid or hematologic cancers. The assess-
ment was conducted by an ad hoc form to collect socio-demo-
graphic and clinical- oncological data, the PHQ-9 to screen MDD
(cut-off ≥10) and the SF-12 to evaluate HRQoL. Relative Risk
(RR) of early death between MDD exposed and not-exposed and
Kaplan-Meier survival were carried out.
Results: people exposed to MDD during the follow-up were
107/263 (40.7%). Among them, 36 deceased during the observa-
tion period. Overtime, having MDD and death’ occurrence
showed a strong association (RR=2.15; 95% CI (1.10-4.20);
χ²=5.224, p=0.0022), confirmed by Kaplan-Meier survival analy-
sis (χ²=4.357, p=0.037). Among people who died, there was not
any association between MDD, age, gender, HRQoL, cancer stage
and site.
Conclusions: the study confirms the association between
MDD and early death in people with cancer. The absence of any
association between the onset of MDD and advanced stage of can-
cer may suggest that it could be due to the consequences of MDD
in worsening the clinical conditions related to cancer. The findings
point out the relevance of MDD’ early detention among people
with cancer.
Introduction
Major Depressive Disorder (MDD) is a recurring condition
and a leading source of disability worldwide.1,2 MDD is associat-
ed with impairment of Health-related Quality of Life (HRQoL)
and with premature death for all-cause of mortality,4,5 included
suicide.6 People suffering from depression have high rates of
comorbidity with other psychiatric and non- psychiatric disor-
ders;7 some studies showed that comorbid condition with MDD
had worsened prognosis and showed higher mortality of the same
conditions without depression.5,8-10 However, this data is still
poorly confirmed, and the causal links of this association are not
well clarified yet.
The World Health Organization pointed out that, in 2018, 9.6
million people worldwide are died from cancer.11 The prevalence
of MDD among individuals with cancer is approximately 12.5%,
which is up to four-times the rate reported in population-based
samples, that is around 3.3%.10,12
Among patients with cancer, MDD was shown to be associat-
ed with a variety of negative clinical outcomes, such as poor com-
pliance with anti-cancer treatment13 and low level of HRQoL.14-17
Several studies found that people suffering from cancer with
comorbid MDD had higher early death risk.5,8,10,18 However, as
described above for the general comorbidity of MDD with other
diagnosis, so far little evidence has been accumulated to try to
understand the causal link between early death and MDD in peo-
ple suffering from cancer.
The primary end point of the present study was to verify the
association between MDD episode over time (9 months) and high-
er death risk in people with solid and hematological cancers in a
prospective analysis. Another aim was to establish if there were
differences between other outcome indicators in the group of peo-
ple with early death and, particularly, if the onset of MDD is asso-
ciated with worse severity in the evolution of the tumor pathology.
This is, in fact, a fundamental element to begin to understand
whether it is depression that causes worsening in clinical condi-
tions and death or vice-versa.
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Significance for public health
This cohort study lasting 9 months pointed out a high prevalence of Major Depressive Disorder (MDD) among people with cancer. During the time of obser-
vation, 36 deceases occurred. A strong association was observed regarding the survival rates between the MDD exposed subjects who died along the time and
the MDD not exposed who survived. This association could be due to the consequences of MDD, if considering that it was not found any significant association
between MDD among patients who died and a worse HRQoL when the MDD episode had been occurred, nor with age, gender, cancer stage and site. These find-
ings point out the importance of the early detention of MDD among people with cancer, to promptly provide effective interventions for a good management of
symptoms related to cancer and depression. Further studies are needed to explore the causal association between MDD and premature death in people suffering
from cancer.
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Design and Methods
Study design
It is a cohort study, lasted 9 months. Among a study population
of people with solid or hematological cancers, two cohorts were
assessed: one included people exposed to at least one MDD
episode (MDD-E) during the observation period; the other one was
composed by MDD not- exposed (MDD-NE). The main outcome
was the number of deaths in the two cohorts. People in the cohort
with depression were those that, at the baseline, showed a depres-
sive episode or those that had the onset of depressive episode dur-
ing the observational period (changing of cohort).
Furthermore, we also built a case control study on the cohort
(cases: people with depressive episode; controls: people without
depressive episode), to verify the factors associated with death at
the beginning of the study.
Recruitment procedures, study sample issues
Since 2018, the study has been conducting in Cagliari, Italy, at
the Oncology Unit, University- Hospital and at the Hematology
Unit and Stem Cell Transplantation Center, “Businco” Hospital.
The study population includes people aged≥18 years, of both gen-
ders, with histologic confirmation of a solid or hematologic malig-
nant cancer and receiving active anti-cancer treatment. After the
baseline evaluation (T0), the study protocol includes a series of
repeated measures for each subject: after 3 (T1), 6 (T2) and 9
months (T3) from T0.
Assessment tools
Ad-hoc form was used to collect socio-demographic and clin-
ical-oncological anamnestic data: gender; age; marital status;
employment status; educational level; kind of the oncology serv-
ice; time from taking in charge at the oncology unit; cancer site and
stage; intent of treatment; toxicity of treatments according to
Common Toxicities Criteria for Adverse Events (CTCAE),19
response and adherence to treatment.
The Italian Version20 of the “Patient Health Questionnaire”
(PHQ-9) [21] was used to assess depressive symptoms in the last
two weeks. The PHQ-9 is a self-questionnaire usually used in pop-
ulation studies that could be administered also by phone for
screening MDD or for the evaluation of the severity of depressive
symptoms. It is relatively feasible, pointing out scores to each of
the nine DSM-IV-TR criteria for MDD, proposed in the form of 9
item. As a continue variable to establish the severity of depressive
symptoms, the scores of each item can range from 0 (complete
absence) to 3 (almost every day). To screen MDD, the total score
assigns ranks within the following: 0-4 (minimal), 5-8 (mild), 9-14
(moderate), 15-19 (moderately severe), 20-27 (severe).
The Italian version22 of the self-report questionnaire “Short
Form Health Survey - 12 item” (SF- 12)23 was administered to
evaluate the perceived HRQoL in the last month. The instrument
includes 12 items and investigates two sub-dimensions (physical
and psychosocial health). The total score ranges from 12 to 47,
with higher scores reflecting a better perceived HRQoL.
Statistical analyses
Data collection and data-entry in a dedicate database were
anonymously for each subject. Data were analyzed with the
Statistical Package for Social Science (SPSS) version 24 (Chicago,
IL, USA). Descriptive statistics were used for continuous
(mean±SD; N and %) and nominal (N and %) variables, to point
out the socio-demographic and clinical-oncological characteristics
of the samples at the baseline (T0), after 3 months (T1), 6 months
(T2) and 9 months (T3), data regard N (%) of evaluated patients.
PHQ-9 score ≥10 was used to define MDD-E subjects during the
period of observation. To calculate the Relative Risk (RR), the two
cohorts (MDD-E and MDD-NE) were evaluated overtime about
the death’ and other inauspicious outcomes’ incidences by χ² test
and the Kaplan-Meier survival function. One-way ANOVA,
Kruskal-Wallis and χ² test were used to evaluate the association
between MDD and HRQoL, age, gender, cancer stage and site at
T0, as well as between MDD-E subjects who died overtime and
HRQoL when the MDD episode had been occurred, age, gender,
cancer stage and site at T0.
Results
The study cohort includes N 263 people with solid (201,
76.4%) and hematologic cancers (62, 23.6%) (Table 1). Women
were 132 (50.2%); the mean±SD age was 61.2±13.6 years. More
than half had a high-school diploma or a university degree (139;
52.6%). Most of the subjects were married (175; 66.5%), 57
(21.7%) singles, 10 (3.8%) divorced and 21 widows (8%); (see
Table 1 for details and the other characteristics of the study
cohort). 
People with a depressive episode during the cohort were
107/263 (40.7%), people without 156/263 (59.3%). Along time of
the observation, in the “MDD-Exposed” cohort, months/person
were 586.5. In the “MDD-Not Exposed” cohort, months/person
were 900 (Table 2). 
Table 2 also shows that, at T1, after 3 months from the base-
line, n 23 (8.7%) people were deceased, at T2, after 6 months from
the baseline, other n 11 (4.2%) people were deceased and at T3,
after 9 months from the baseline, other n 2 (0.8%) people were
deceased. Furthermore, considering the 36 deaths occurred in the
overall sample, 21 occurred in the cohort of people exposed to
MDD (MDD- E) and 15 in the cohort of people not exposed to
MDD (MDD-NE), the Relative Risk (RR) was=2.15; 95% CI
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Figure 1. Kaplan-Meier survival function: differences about
Major Depressive Disorder (MDD) exposed and not exposed
subjects who survived over time (9 months).
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(1.10-4.20); χ²=5.224, p=0.0022), the Kaplan-Meier survival curve
confirmed the result (Log-Rank Mantel-Cox χ²=4.357, p=0.037;
Table 3, Figure 1).
Table 4 shows that female gender (χ² with Fisher exact
test=4.338, df 1, p=0.045) and a worse HRQoL (F=51.008, df
1,261,262; p=0.000) were significantly associated with MDD.
Finally, as shown in Table 5, among the 21 MDD-E and the 15
MDD-NE subjects who died along the time, the SF-12 mean±SD
scores when the MDD episode had been occurred were 26.7±7.3
and 27.6±5.7 respectively, without any significant difference.
Considering age, gender, the cancer stage and site at T0, there were
not any significant difference between the two groups.
Discussion
The present study pointed out that, according to PHQ-9≥10
score, 40.7% patients with a solid or hematological cancer present-
ed at least one MDD episode along the time of observation. This
data is higher if compared with a previous meta-analyses24 that
pointed out a pooled mean prevalence of depression in patients
with cancer ranged from 8% to 24%, depending by the type of
instrument used to assess MDD (other self-report questionnaire
different from PHQ-9 or semi-structured diagnostic interviews
based on DSM-III-R/IV or ICD-10 criteria), the type of cancer and
treatment phase. However, the use of PHQ-9 as MDD screening
instrument in the oncological field is high recommended25-27 and,
ideally, it might be followed by an evaluation by a semi-structured
interview based on DSM or ICD criteria (i.e., SCID) when the
costs and benefits of routinely screening all patients with cancer
admit to use of both kind of tools.27 This is not the case of the pres-
ent study, in which the assessment was carried out only by self-
reported instruments. Hence, the higher MDD prevalence obtained
should be confirmed by diagnoses obtained with semi-structured
interviews, also because of the PHQ-9 ≥10 score used as the cut-
off to detect MDD exposed patients. In fact, this is a threshold usu-
ally recommended for screening general medical and primary care
patients, but it allows to reduce the number of MDD false-positive
subjects at the cost of missing more false-negatives,26 and this
could be a limitation. The study confirms also that MDD is more
prevalent among women2,28 and that MDD is associated with a
worse HRQoL in people suffering from cancer.3,14,15,17
Furthermore, the present study pointed out that, from the base-
line, 36 deceases occurred. A significant difference in the Relative
Risk (RR) was observed regarding only the survival rates between
the 21 MDD exposed subjects who died along the time and the 15
MDD not-exposed subjects who survived. There could be two
main hypotheses to explain this association.
One of these regards the impact of the MDD in worsening the
clinical conditions of people suffering from cancer, precipitating
the occurrence of death. Patients with cancer and MDD could suf-
fer from a significant distress and impaired functioning, such as a
lack of interest in daily activities, including the poor inclination to
taking care of themselves, as well as from several disturbances in
sleeping and eating. Otherwise, patients with cancer could just
start to “let themselves go” because of the worsening in their clin-
ical conditions due to cancer, resulting in a bad mood that could
degenerate in MDD episode. Both hypotheses could be right.
However, findings pointed out any significant association
between MDD episodes among patients who died and a worse
HRQoL when the MDD episode had been occurred, nor with other
factors such as age, gender and the cancer stage and site at T0
(baseline). This is an important indication that may confirm the
                            [Journal of Public Health Research 2021; 10:2247]                                            [page 563]
                                                                                                    Article
Table 1. Socio-demographic and clinical characteristics of the
study sample.
Variable                                 n                                  %
Gender                                                Male                                    131          49.8
                                                              Female                                132          50.2
Marital status                                    Single                                   57           21.7
                                                              Married                               175          66.5
                                                              Divorced                              10            3.8
                                                              Widow                                  21             8
Employment status                          Housewife                           32           21.2
                                                              Unemployed                       13            8.6
                                                              Employed                            49           31.5
                                                              Retired                                 57           37.7
Education level                                  <Primary school                 1             0.4
                                                              Primary school                   32           12.2
                                                              Secondary school              93           35.4
                                                              High school                        100           38
                                                              University degree              32           12.2
                                                              Military Academy                1             0.4
                                                              Higher                                   4             1.5
Kind of service                                  Day hospital                       217          82.5
                                                              Hospital ward                     46           17.5
Timing of taking care at the           First visit                              9             3.4
Oncology service                              <6 months                         102          38.8
                                                              6-12 months                        48           18.3
                                                              >12 months                       103          39.2
                                                              Not evaluated                      1             0.4
Cancer site                                         Gastroenteric                     94           35.7
                                                              Gynecological                     32           12.2
                                                              Breast                                  32           12.2
                                                              Lung                                     16            6.1
                                                              Head and neck                    1             0.4
                                                              Rare                                       9             3.4
                                                              Uro-genital                          17            6.5
Cancer stage                                      1                                             10            3.8
                                                              2                                             29            11
                                                              3                                             45           17.1
                                                              4                                            178          67.7
                                                              Not evaluated                      1             0.4
Toxicity of treatments*                   0                                             72           47,7
                                                              1                                             25           16,6
                                                              2                                             38           25,2
                                                              3                                             14            9,3
                                                              4                                              2             1,3
Intent of treatment                          Adjuvant                               41           15.6
                                                              New adjuvant                       4             1.5
                                                              Curative                               31           11.8
                                                              Palliative                             156          59.3
                                                              Maintenance                       25            9.5
                                                              Support                                 5             1.9
                                                              Not evaluated                      1             0.4
Response to treatment                   Absence of cancer            38           14.4
                                                              Ongoing                               82           31.2
                                                              In progress                         47           17.9
                                                              Partial                                  25            9.5
                                                              Stable                                   65           24.7
                                                              Not evaluated                      6             2.3
Adherence after 3 months             No                                         27           10.3
of treatment                                      Yes                                       229          87.1
                                                              Not evaluated                      7             2.7
*The toxicity of treatment was scored from 0 (mild) to 4 (death), according to common toxicities crite-
ria. (CTC), version 4.019; available from: https://ctep.cancer.gov/protocoldevelopment/electronic_appli-
cations/ctc.htm#ctc_50
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Table 2. The association between MDD “positive-exposed” subjects according to PHQ-9 ≥10 score and deceases occurred from T0 to
T3 (9 months).
                                                                                        PHQ-9 ≥10 “positive”           PHQ-9<10 “negative”                             Total
                                                                                          (exposed to MDD)            (not exposed to MDD)                               
From T0 to T3 (9 months), n (%)                                                                   107 (40.7%)                                        156 (59.3%)                                             263 (100%)
Months/person (sum)                                                                                            586.5                                                      900                                       9 months (from T0 to T3)
Deceases (after 3 months from the baseline - T1), n (%)                                                                                                                                                        23 (8.7%)
Deceases (after 6 months from the baseline – T2), n (%)                                                                                                                                                       11 (4.2%)
Deceases (after 9 months from the baseline – T3), n (%)                                                                                                                                                        2 (0.8%)
Deceases (total), n (%)                                                                                    21 (58.3%)                                          15 (41.7%)                                               36 (100%)
Relative risk                                                                                                                                                                                                                                        2.15; 95% CI
                                                                                                                                                                                                                                                       (1.10-4.20) χ²=5.224,
                                                                                                                                                                                                                                                                  p=0.0022
Table 3. Kaplan-Meier survival analysis about MDD exposed and not exposed subjects who died over time (9 months).
Status                         Total       n deceased Censored (survivors)        Associations                           Χ² test         Df                    p
                                                                                    n                     %                                                                                     
MDD exposed                       107                      21                             86                       80.4%               Log-rank (mantel-cox)                       4.357                1                        0.037
MDD not exposed               156                      15                           141                      90.4%               Breslow (generalized wilcoxon)     3.884                1                        0.049
                                                                                                                                                                 Tarone-ware                                         4.133                1                        0.042
MDD, Major Depressive Disorder. 
Table 4. Factors associated with MDD (PHQ-9 ≥10) in the overall sample.
                        SF-12 mean±SD (T0)   Age mean±SD             Gender F/M n (%)       Cancer stage at T0 (1,2,3,4)        Cancer site at T0
PHQ-9                                   29.05±6.3                          61.2±14.3                                   F=62/107                                       Stage 1= 6/107                                 Blood= 22/107
≥10                                                                                                                                          (57.9%)                                               (5.6%)                                                (21%)
“positive”                                                                                                                                                                                                                                               Breast= 15/107
(exposed                                                                                                                             M=45/107                                      Stage 2= 9/107                                        (14%)
to MDD)                                                                                                                                (42.1%)                                               (8.4%)                                       Gastroenteric=
                                                                                                                                                                                                                                                                    41/107 (38%)
n=107                                                                                                                                                                                          Stage 3= 18/107                               Gynecological=
                                                                                                                                                                                                             (16.8%)                                        12/107 (11%)
                                                                                                                                                                                                                                                                Head and neck=
                                                                                                                                                                                                     Stage 4= 74/107                                   0/107 (0%)
                                                                                                                                                                                                             (69.2%)                                    Lung= 4/107 (4%)
                                                                                                                                                                                                                                                               Rare= 3/107 (3%)
                                                                                                                                                                                                                                                                   Uro-genital=
                                                                                                                                                                                                                                                                     10/107 (9%)
PHQ-                                      34.3±5.5                           61.2±13.2                                   F=70/156                                       Stage 1= 4/156                                 Blood= 40/156
9<10                                                                                                                                       44.9(%)                                               (2.6%)                                                (25%)
“negative”                                                                                                                                                                                                                                               Breast= 17/156
(not                                                                                                                                       M=86/156                                     Stage 2= 20/156                                       (11%)
exposed to                                                                                                                            (55.1%)                                              (12.8%)                                      Gastroenteric=
MDD)                                                                                                                                                                                                                                                         53/156 (34%)
                                                                                                                                                                                                     Stage 3= 27/156                               Gynecological=
n=156                                                                                                                                                                                                 (17.3%)                                        20/156 (13%)
                                                                                                                                                                                                                                                                Head and neck=
                                                                                                                                                                                                    Stage 4= 104/156                                  1/156 (1%)
                                                                                                                                                                                                             (66.7%)                                   Lung= 12/156 (8%)
                                                                                                                                                                                                                                                               Rare= 6/156 (4%)
                                                                                                                                                                                                      Not reported=                            Uro-genital= 7/156
                                                                                                                                                                                                        1/156 (0.6%)                                           (4%)
One-way                               F=51.008,                           F=0.001,                                                                                                                                                                    
ANOVA                                         df                                        df                                                                                                                                                                          
                                               1,261,262                            1,261,262                                                                                                                                                                    
χ²                                                                                                                                           4.338, df 1                                                                                                      6.332, df 7
Kruskal-Wallis                                                                                                                                                                                 0.082, df 1                                                   
p                                                 0.000                                   0.978                                          0.045*                                                  0.774                                                 0.499*
MDD, Major Depressive Disorder; *Fisher exact test.
role of MDD in worsening the clinical conditions of people suffer-
ing from solid or hematological cancers, also by increasing the
death risk.
Other studies pointed out that MDD or severe depressive
symptoms are independent risk factors for cancer mortality, mainly
when cancer is in advanced stadium,29,30 with a 26% greater mor-
tality rate among patients with depressive symptoms and a 39%
higher mortality rate among those with a diagnosis of MDD.9
Otherwise, differently also from the findings of the present
study, some research showed that the impact of MDD on mortality
rate may change by cancer site: being higher in people with lung,
gastrointestinal and brain cancer, and lower in those with urogeni-
tal and skin cancer.31 In any case, an amount of studies, conducted
also by animal models, agreed on some hypothesis to explain the
relation between depression and cancer, mainly from behavioral
and neuro-biological perspectives.9,10,32-35 One hypothesis regards
the chronic activation of the hypothalamus-pituitary-adrenal
(HPA) axis, that could be a mediator of the effect of depression on
cancer progression:35 an excessive activation of the HPA axis may
modify the functioning of the cellular immune system, increasing
the potential for malignant cancer fast progression.
Furthermore, pro-inflammatory cytokines (i.e., interleukin-1α
and β, tumor necrosis factor-α, interleukin-6) are modified by emo-
tions, and have been shown to increase in depression by a dysreg-
ulated production and functioning linked also to a disrupted HPA
axis activation that may influence cancer outcomes and progno-
sis.34-36
Other hypotheses regard the role of psychosocial stressors as
modulators of immune response in depression and cancer.10
Particularly, poor social support, lack of familiar bonding, a history
of childhood trauma and adverse life experiences increase the vul-
nerability to chronic diseases, including MDD and cancer,37 as
well as to cancer mortality across several kinds of cancer.30
Particularly, these psychosocial factors are associated with cogni-
tive difficulties, mainly on memory, which could have a role in
diminishing treatment compliance,10 as well as with unhealthy
lifestyle, such as delay in treatment-seeking, eating and sleeping
habits, smoking and alcohol abuse, lack of physical activity.30
Notably, findings of the present study showed another interest-
ing data regarding patients who died along the time of observation.
Even if mostly of these patients, both those exposed or not exposed
to MDD, exhibited a severe cancer stadium (the 4th) at the baseline,
there was not any significant association between this variable and
the occurrence of MDD episodes along the time, nor with the can-
cer site as already said above. These evidences confirm that MDD
may precipitate the clinical outcomes of patients with cancer and
increases their death risk. Furthermore, this data points out the
importance of the early detention of depressive symptoms and
other early signs of psychosocial distress in this kind of population
by prompt and reliable screening interventions. In this way, it is
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Table 5. Factors associated with death in the overall sample [MDD (PHQ-9 ≥10)].
                              SF-12 mean±SD                     Age mean±SD         Gender F/M            Cancer stage at T0              Cancer site at T0
               (corresponding to MDD episode)                                             n (%)                           (1,3,4)                                        
PHQ-9 ≥10                              26.7±7.3                                            63.3±13.1                        F=11/21                                    Stage                                      Blood=0/21 (0%)
“positive”                                                                                                                                     (52.4%)                              1=1/21 (5%)                               Breast=1/21 (5%)
(exposed to                                                                                                                                                                                                                                Gastroenteric=14/21
MDD) who                                                                                                                                  M=10/21                                   Stage                                                (66%)
died                                                                                                                                               (47.6%)                                   3=3/21                                  Gynecological=1/21
                                                                                                                                                                                                         (14%)                                                (5%)
n=21                                                                                                                                                                                                                                             Head and neck=0/21
                                                                                                                                                                                                          Stage                                                 (0%)
                                                                                                                                                                                                        4=17/21                                   Lung=2/21 (9.5%)
                                                                                                                                                                                                         (81%)                                      Rare=1/21 (5%)
                                                                                                                                                                                                                                                          Uro-genital=2/21
                                                                                                                                                                                                                                                                   (9.5%)
PHQ-9<10                               27.6±5.7                                            65.7±12.3                         F=4/15                                     Stage                                    Blood=1/15 (6.7%)
“negative”                                                                                                                                    (26.7%)                              1=0/15 (0%)                             Breast=1/15 (6.7%)
(not exposed                                                                                                                                                                                                                               Gastroenteric=8/15
to MDD)                                                                                                                                      M=11/15                                   Stage                                              (53.1%)
who died                                                                                                                                       (73.3%)                                   3=2/15                                  Gynecological=1/15
                                                                                                                                                                                                         (13%)                                               (6.7%)
n=15                                                                                                                                                                                                                                             Head and neck=1/15
                                                                                                                                                                                                          Stage                                               (6.7%)
                                                                                                                                                                                                        4=13/15                                   Lung=1/15 (6.7%)
                                                                                                                                                                                                         (87%)                                     Rare=1/15 (6.7%)
                                                                                                                                                                                                                                                          Uro-genital=1/15
                                                                                                                                                                                                                                                                   (6.7%)
One-way ANOVA                   F=0.168,                                             F=0.310,
                                                   df 1,34                                                 df 1,34                                                                                                                                             
χ²                                                                                                                                                   2.380, df                                4.228, df 7
                                                                                                                                                             1                                                                                                          
Kruskal-Wallis                                                                                                                                                                            0.246, df 1                                                  
p                                                   0.684                                                    0.582                              0.176*                                      0.620                                                0.902*
MDD, Major Depressive Disorder; *Fisher exact test.
                                                               [Journal of Public Health Research 2021; 10:2247]                                            [page 565]
possible to support people suffering from cancer in managing the
impact of MDD since its early signs. In addition to antidepres-
sant,13 several psychosocial interventions may be effective in
improving depressive symptoms and psychosocial distress, by
enhancing resilience, social support and adaptive coping strategies
to stress management, such as cognitive behavioral therapy, mind-
fulness- based therapy, multimodal approaches including psychoe-
ducational interventions, counseling, hypnosis and relaxation tech-
niques, therapeutic dialogue provided by a “trained helper”, moti-
vational interviewing.10,38-40
The present study has some limitations. Firstly, the small sam-
ple size did not allow to perform robust analyses for confounding
factors, regarding all the variables that may be associated with
death’ risk in people with cancer (i.e., the kind of hematologic can-
cer). The analyses performed in this study allowed to point out just
several associations with MDD exposition, without establish a
cause-effect direction. Furthermore, MDD exposition was evaluat-
ed just by a self-report screening instrument (PHQ-9), without a
standardized diagnostic interview based on DSM or ICD criteria.
Finally, it was estimated the sum months/person to fix the
occurrence of the decease and the MDD episode just on the basis
of the timing of observation (3 months from one to another evalu-
ation, until 9 months) by the mean about months elapsed between
successive evaluations.
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